Treatment ofHelicobacter pyloriinfection: Past, present and future
Author:
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 5 (4) , 392-9
Abstract
Helicobacter pylori (H. pylori) is a major human pathogen associated with significant morbidity and mortality. However, after decades of efforts, treatment of H. pylori remains a challenge for physicians, as there is no universally effective regimen. Due to the rising prevalence of antimicrobial resistance, mainly to clarithromycin, efficacy of standard triple therapies has declined to unacceptably low levels in most parts of the world. Novel regimens, specifically experimented to improve the therapeutic outcome against antibiotic-resistant H. pylori strains, are now recommended as first-line empirical treatment options providing high efficacy (reportedly > 90% in intention to treat analysis) even in high clarithromycin resistance settings. These include the bismuth quadruple, concomitant, sequential and hybrid therapies. Due to the rapid development of quinolone resistance, levofloxacin-based regimens should be reserved as second-line/rescue options. Adjunct use of probiotics has been proposed in order to boost eradication rates and decrease occurrence of treatment-related side effects. Molecular testing methods are currently available for the characterization of H. pylori therapeutic susceptibility, including genotypic detection of macrolide resistance and evaluation of the cytochrome P450 2C19 status known to affect the metabolism of proton pump inhibitors. In the future, use of these techniques may allow for culture-free, non-invasive tailoring of therapy for H. pylori infection.Keywords
This publication has 83 references indexed in Scilit:
- Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin ResistanceThe Journal of Infectious Diseases, 2013
- Adjuvant probiotics improve the eradication effect of triple therapy forHelicobacter pyloriinfectionWorld Journal of Gastroenterology, 2012
- Treating Bugs with Bugs: The Role of Probiotics as Adjunctive Therapy for Helicobacter pyloriAnnals of Pharmacotherapy, 2011
- Should quinolones come first in Helicobacter pylori therapy?Therapeutic Advances in Gastroenterology, 2010
- Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled TrialsInternal Medicine, 2009
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Evaluation of seaFAST, a Rapid Fluorescent In Situ Hybridization Test, for Detection of Helicobacter pylori and Resistance to Clarithromycin in Paraffin-Embedded Biopsy SectionsJournal of Clinical Microbiology, 2005
- High eradication rates of Helicobacter pylori with a new sequential treatmentAlimentary Pharmacology & Therapeutics, 2003
- Factors that May Affect Treatment Outcome of Triple Helicobacter pylori Eradication Therapy with Omeprazole, Amoxicillin, and ClarithromycinDigestive Diseases and Sciences, 2000